دورية أكاديمية
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.
| العنوان: | Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity. |
|---|---|
| المؤلفون: | Callenbach MHE; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands., Goettsch WG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands; National Health Care Institute (ZIN), Diemen, the Netherlands., Mantel-Teeuwisse AK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands., Trusheim M; NEWDIGS, Tufts Medical Center, Boston, MA, USA. Electronic address: mark.trusheim@tuftsmedicine.org. |
| المصدر: | Drug discovery today [Drug Discov Today] 2024 Jul; Vol. 29 (7), pp. 104048. Date of Electronic Publication: 2024 Jun 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd. Country of Publication: England NLM ID: 9604391 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5832 (Electronic) Linking ISSN: 13596446 NLM ISO Abbreviation: Drug Discov Today Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kidlington, Oxford : Irvington, NJ : Elsevier Science Ltd. ; Distributed by Virgin Mailing and Distribution, c1996- |
| مواضيع طبية MeSH: | Cell- and Tissue-Based Therapy*/methods , Genetic Therapy*/methods, Humans ; Netherlands ; Reimbursement Mechanisms ; Technology Assessment, Biomedical ; United Kingdom ; United States |
| مستخلص: | Outcome-based reimbursement models are gaining attention for managing the clinical uncertainties and financial impact of gene and cell therapies. Little guidance exists on how such models can create win-win-win situations, benefiting health-care payers, health-technology developers and patients. Our innovative approach prospectively prioritizes therapies for which a 'window of opportunity' might occur through the analysis of health-technology assessments and product characteristics. Within this window, one size does not fit all, and depending on the extent of clinical uncertainty and potential added benefit levels, different win-win-win situations exist in the United States, the United Kingdom and the Netherlands. Dutch Horizon scanning data prioritized etranacogene dezaparvovec (Hemgenix) and mozafancogene autotemcel for their potential to benefit from outcome-based reimbursement models. These insights extend beyond gene and cell therapies, and could help to provide sustainable health care and patient access to innovative therapies. (Copyright © 2024. Published by Elsevier Ltd.) |
| فهرسة مساهمة: | Keywords: ATMPs; Delayed payments; Gene and cell therapies; Horizon scanning; Managed entry agreements; Outcome-based reimbursement |
| تواريخ الأحداث: | Date Created: 20240603 Date Completed: 20240706 Latest Revision: 20240708 |
| رمز التحديث: | 20240709 |
| DOI: | 10.1016/j.drudis.2024.104048 |
| PMID: | 38830504 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1878-5832 |
|---|---|
| DOI: | 10.1016/j.drudis.2024.104048 |